At AstraZeneca we are committed to pushing the boundaries of oncology research. With patients at the core of everything we do, we continue to drive towards transforming the oncology therapy landscape. Our science-led approach is continually evolving and we are pleased to be presenting our latest data on both pipeline and marketed products at Europe’s premier cancer meeting, the European Society for Medical Oncology (ESMO) 2017 Congress in Madrid, Spain.
To keep updated, follow us on Twitter at @AstraZeneca and join the ESMO conversation at #ESMO17.
Veeva ID: Z4-6714
Date of next review: August 2018